Shandong Xinhua Pharmaceutical Co (HKSE:00719) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shandong Xinhua Pharmaceutical Co EBITDA Margin % Related Terms
Shandong Xinhua Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co EBITDA Margin % Chart
HKSE:00719 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Xinhua Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co (HKSE:00719) has a EBITDA Margin % of 5.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. This is 61% below median its historical median of 13.42. Over the past decade, Shandong Xinhua Pharmaceutical Co's EBITDA Margin % has ranged from 4.28 to 14.27. According to the industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #657 out of 954 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is Shandong Xinhua Pharmaceutical Co's EBITDA Margin % too high?
Shandong Xinhua Pharmaceutical Co's current EBITDA Margin % of 5.24% is 61% below median its 10-year median of 13.42. Over the past 10 years, this metric has ranged from a low of 4.28 to a high of 14.27. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Shandong Xinhua Pharmaceutical Co's value of 5.24% is 58.1% below this industry median. Based on the distribution chart, Shandong Xinhua Pharmaceutical Co ranks #657 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #657 out of 954 companies for EBITDA Margin %. This places Shandong Xinhua Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Shandong Xinhua Pharmaceutical Co's value of 5.24% is 58.1% below this benchmark. Historically, Shandong Xinhua Pharmaceutical Co's own EBITDA Margin % has ranged from 4.28 to 14.27 over the past decade. While the company's 10-year median is 13.42 vs. the industry median of 12.52, Shandong Xinhua Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Xinhua Pharmaceutical Co's current EBITDA Margin % of 5.24% is 58.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Xinhua Pharmaceutical Co's current EBITDA Margin % is 5.24%, which is 61% below median its own 10-year median of 13.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co (HKSE:00719) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$7.57, compared to a current price of HK$5.87 — trading 22.5% below its estimated fair value. The current EBITDA Margin % is 5.24%, which is 61% below median its 10-year median of 13.42 and 58.1% below the Drug Manufacturers industry median of 12.52. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (HKSE:00719), the current EBITDA Margin % is 5.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Xinhua Pharmaceutical Co (HKSE:00719) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued.
The current stock price of HK$5.87 is trading 22.5% below its estimated GF Value™ of HK$7.57.
GuruFocus considers Shandong Xinhua Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for HKSE:00719:
EBITDA Margin %: 5.24% (61% below median its 10-year median of 13.42)
GF Value™: HK$7.57 vs. price of HK$5.87 (22.5% below fair value)
Industry Position: 58.1% below the Drug Manufacturers median (#657 of 954)
No single metric tells the full story. See the HKSE:00719 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Xinhua Pharmaceutical Co Business Description
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
94GF Score
Get the complete analysis for HKSE:00719
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00719 has been successfully added to your 
